
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Gemin8 CRISPR Activation Plasmid (h) | sc-404145-ACT | 20 µg | $397.00 |
GEMIN8 encodes Gemin8, a core component of the SMN–Gemin complex that supports assembly of spliceosomal small nuclear ribonucleoproteins (snRNPs) required for pre-mRNA splicing. Through its role in snRNP biogenesis and spliceosome homeostasis, Gemin8 contributes to RNA processing fidelity and broader regulation of gene expression programs. Perturbation of SMN-complex activity is linked to neuromuscular and neurodevelopmental disease mechanisms and can impact cell viability and stress responses via altered RNA metabolism. GEMIN8 is therefore relevant for studying spliceosome-associated pathways, RNA-protein complex assembly, and disease-relevant transcriptome dysregulation in human cells.
Gemin8 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous GEMIN8 expression without altering the underlying DNA sequence.
Gemin8 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the GEMIN8 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the GEMIN8 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Gemin8 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native GEMIN8 locus and enabling the study of Gemin8-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Gemin8 pathway restoration in tumor cells with silenced or reduced GEMIN8 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.